Bluejay Diagnostics (BJDX) AI Stock Analysis

• Market Cap: $1.18M
• Dividend Yield: N/A
• Average Volume (3M): 5.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: N/A
• EPS Growth: 97.70%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 1,814,133
• 10 Day Avg. Volume: 15,571,172
• 30 Day Avg. Volume: 5,266,425
• PEG Ratio: <0.01
• Price to Book (P/B): 0.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.11
• Enterprise Value/Market Cap: -0.72
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.13
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.63 ▼(-6.76% Downside)

The score is held down primarily by weak financial fundamentals (no revenue, large losses, and negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Positive corporate execution milestones provide some offset, but valuation is constrained by lack of profitability and no dividend support.

Positive Factors

Strategic Partnerships

The expanded partnership with SanyoSeiko enhances manufacturing and supply chain capabilities, crucial for scaling production and ensuring quality control, supporting long-term growth and operational efficiency.

Product Development

Commercial-scale production of antibodies for IL-6 assays strengthens Bluejay's product portfolio, supporting future clinical and commercial applications, and positioning the company for growth in the sepsis diagnostics market.

Clinical Progress

Ongoing SYMON-II trial for the IL-6 test is crucial for FDA submission and potential market entry, enhancing Bluejay's competitive position in the sepsis diagnostics market.

Negative Factors

Financial Performance

The lack of revenue and persistent losses highlight financial instability, posing significant risks to sustainability and necessitating further capital to support operations and growth.

Cash Flow Challenges

Negative cash flow indicates ongoing funding needs, limiting Bluejay's ability to self-finance and potentially hindering long-term strategic initiatives without additional capital.

Funding Requirements

Significant future capital requirements pose a risk to execution and growth plans, as securing necessary funding is uncertain and could dilute existing shareholders.

Bluejay Diagnostics Business Overview & Revenue Model

Company Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Bluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.

Bluejay Diagnostics Financial Statement Overview

Summary

Bluejay Diagnostics faces considerable financial challenges, with no revenue generation and persistent net losses over several years. While there have been improvements in equity, the overall financial health remains weak, reflecting high risk and dependency on external financing. Stabilizing revenue and improving cash flow management are critical for future growth and sustainability.

Income Statement

The company has consistently reported zero revenue with negative net income over multiple years. The lack of revenue growth and persistent net losses indicate a significant challenge in achieving profitability. This situation reflects a high risk in the income statement.

Balance Sheet

The company shows a substantial improvement in stockholders' equity from negative to positive, which is a positive sign. However, the debt-to-equity ratio is unfavorable due to high total liabilities relative to equity, and the equity ratio has been fluctuating. These mixed results indicate some improvements but also ongoing financial instability.

Cash Flow

Operating and free cash flows have been consistently negative, indicating operational difficulties. Although financing activities have provided cash inflows, reliance on external financing could be unsustainable. The cash flow situation suggests significant cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	249.04K	0.00	0.00
Gross Profit	0.00	0.00	0.00	48.91K	-145.72K	-157.04K
EBITDA	-6.74M	-6.70M	-9.17M	-9.01M	-3.08M	-1.04M
Net Income	-6.85M	-7.72M	-9.95M	-9.30M	-3.73M	-1.13M
Balance Sheet
Total Assets	4.89M	6.66M	4.87M	13.52M	21.02M	1.52M
Cash, Cash Equivalents and Short-Term Investments	3.08M	4.30M	2.21M	10.11M	19.05M	912.36K
Total Debt	142.99K	222.25K	352.98K	492.62K	0.00	1.06M
Total Liabilities	1.20M	927.92K	1.97M	1.98M	637.16K	5.72M
Stockholders Equity	3.69M	5.73M	2.89M	11.54M	20.38M	-4.21M
Cash Flow
Free Cash Flow	-6.34M	-8.13M	-9.02M	-8.94M	-4.39M	-508.71K
Operating Cash Flow	-6.34M	-7.82M	-8.31M	-7.74M	-4.37M	-508.71K
Investing Cash Flow	-1.13K	-306.78K	-704.17K	-1.20M	-23.95K	0.00
Financing Cash Flow	3.67M	10.22M	1.11M	8.07K	22.53M	1.33M

Bluejay Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 1.24, and below the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 23.96 is Positive, neither overbought nor oversold. The STOCH value of 20.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.

Bluejay Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AEMD	45 Neutral	$2.39M	-0.05	-191.39%	―	―	76.53%
BJDX	44 Neutral	$1.18M	-0.02	-126.20%	―	―	97.70%
TIVC	43 Neutral	$3.41M	-0.15	-178.18%	―	-49.63%	82.22%
VERO	40 Underperform	$2.84M	-0.03	-854.61%	―	-12.39%	44.61%
DHAI	37 Underperform	$6.70K	>-0.01	―	―	―	―

Bluejay Diagnostics Corporate Events

Bluejay Diagnostics Scales IL-6 Antibody Production Capacity

On December 29, 2025, Bluejay Diagnostics announced it had completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a key biomarker for inflammatory and critical-care applications, with both antibody types meeting internal performance criteria for use in Symphony cartridge manufacturing. Internal testing showed acceptable binding, specificity and signal performance for the monoclonal detection antibodies, and the company now estimates its IL-6 antibody inventory could support production of more than nine million Symphony cartridges while also having the capability to produce additional antibodies, marking a significant operational milestone for scaling the Symphony platform even as the system remains under development and subject to further validation and regulatory review.

Bluejay Diagnostics Reports Q3 Results and Updates

On November 10, 2025, Bluejay Diagnostics announced its third-quarter financial results and corporate updates, highlighting advancements in clinical milestones and strategic partnerships. The company reported progress in the SYMON-II clinical trial, aiming for FDA clearance and product commercialization, and completed a private placement transaction in October 2025. Bluejay is focused on sepsis diagnostics, with plans to submit a 510(k) application to the FDA in 2027, contingent on securing further financing.

Bluejay Diagnostics Raises $4M in Private Placement

On October 9, 2025, Bluejay Diagnostics, Inc. announced a private placement of its securities, which closed on October 10, 2025. The company sold 175,000 shares of common stock and warrants to purchase additional shares, raising approximately $4.0 million after fees. The proceeds are intended to fund FDA approval processes, research and development, and general working capital. The private placement includes agreements to register the resale of the securities, with specific restrictions on future stock transactions to protect investor interests.

Bluejay Diagnostics Expands Partnership with SanyoSeiko

On October 3, 2025, Bluejay Diagnostics entered into an amended agreement with SanyoSeiko Co., Ltd. to expand SanyoSeiko’s role in the commercialization of Bluejay’s Symphony platform. This strategic partnership will see SanyoSeiko provide comprehensive support, including manufacturing redevelopment, supply chain management, and quality control, enhancing Bluejay’s supply chain resilience and production capacity for the Symphony platform, which is designed to improve sepsis management.